Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor.
Ramiro-Ibáñez
Fernando
F
Worldwide Safety Sciences, Pfizer Global Research and Development, San Diego, California, 92121, USA. fernando.ramiro-ibanez@pfizer.com
Trajkovic
Dusko
D
Jessen
Bart
B
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000633:toxicity*; D007150:Immunohistochemistry; D008297:Male; D009336:Necrosis; D010179:Pancreas / Q000473:pathology*; D010446:Peptide Fragments / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000473:pathology*; D059005:Topoisomerase II Inhibitors; D014841:von Willebrand Factor / Q000633:toxicity*
D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D059005:Topoisomerase II Inhibitors; D014841:von Willebrand Factor; C081839:von Willebrand factor (445-733); D018844:Cyclin-Dependent Kinases